Moleculin Biotech (MBRX) Stock: Buy, Sell, or Hold?
MBRX - Moleculin Biotech, Inc.
$6.50
0.61 (10.36%)
▲
5d:
+2218.12%
30d:
+1046.59%
90d:
+196.8%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When MBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MBRX is 842.0% above its trading range ($0.69). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MBRX is 842.0% above its trading range ($0.69). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MBRX is currently trading at $6.50, which is considered oversold relative to its 30-day fair value range of $0.39 to $0.69.
Technical Outlook: Technically, MBRX is in a downtrend. The price is approaching resistance at $6.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: MBRX scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $240.00 (+3592.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MBRX is in a downtrend. The price is approaching resistance at $6.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: MBRX scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $240.00 (+3592.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.39 -
$0.69
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.4%)
- BULLISH: Trading 3592.3% below Wall St target ($240.00)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.39 -
$0.69
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$6.59
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.28
Wall Street Target
$240.00
(+3592.3%)
Share & Embed Analysis
Last updated: October 24, 2026 12:03 AM ET
Data refreshes hourly during market hours. Next update: 1:03 AM
Data refreshes hourly during market hours. Next update: 1:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
